Day: April 7, 2025
SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.
A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies.
“Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,” said Sam Raha, incoming president and CEO of Myriad Genetics. “He will be a critical...
P10 Completes Acquisition of Qualitas Funds, a Leading European Lower-Middle Market Alternative Investment Solutions Provider
Written by Customer Service on . Posted in Mergers And Acquisitions.
DALLAS, April 07, 2025 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX) (“P10” or the “Company”), a leading private markets solutions provider, today announced it has completed its previously announced acquisition of Qualitas Equity Funds SGEIC, S.A. (“Qualitas Funds”) for an initial purchase price of $63 million, with the potential for additional earnout consideration.
Qualitas Funds is a Madrid-based private equity investing platform that provides fund-of-funds, direct co-investing and NAV financing opportunities in the European lower-middle market to more than 1,300 limited partners across the ultra-high-net-worth (UHNW), family office, and institutional channels. The firm has approximately $1 billion in fee-paying assets under management (FPAUM) and a strong expected growth trajectory. The firm was founded in 2015 by co-founders and...
Prime Drink Group Announces Its Intent to Acquire Relax Downlow, The Latest Brand to Collaborate with Lane Hutson
Written by Customer Service on . Posted in Mergers And Acquisitions.
With this acquisition, Prime is entering the fast-growing relaxation beverage market, which is expected to reach $1.3 billion by 2030, with a projected CAGR of more than 15%1.
Lane Hutson, NHL star player, becomes the official ambassador of Relax Downlow.
Relax Downlow has just launched its first flavors, Citrus Iced Tea and Tropical Punch, in the largest chain of convenience stores in Quebec and in the upscale hotel sector.MONTREAL, April 07, 2025 (GLOBE NEWSWIRE) — Prime Drink Group Corp. (CSE: PRME) (“Prime” or the “Company”) is pleased to announce that it has entered into a binding letter of intent dated April 3, 2025, to acquire a 70% interest in 9375-4208 Quebec Inc. (the “Target”), a corporation governed by the laws of Quebec (the “Proposed Transaction”). The Target is the owner of Relax Downlow, a brand of recovery functional...
Dundee Precious Metals Annual and Special Meeting of Shareholders to be held May 7, 2025
Written by Customer Service on . Posted in Public Companies.
TORONTO, April 07, 2025 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announces its Annual and Special Meeting of Shareholders will be held on Wednesday, May 7, 2025, at 4 PM EDT via live audio webcast.
Materials for the meeting, including a user guide for accessing the virtual meeting, are available on our website at: https://dundeeprecious.com/investors/investor-centre/#AGMMaterials.
Details of the Annual and Special Meeting of Shareholders, including a link to the audio webcast, are as follows:Webcast date and time
Wednesday, May 7, 20254 PM EDTWebcast link
https://meetnow.global/MXDGNRSReplay
Archive will be available on www.dundeeprecious.comMeeting materials
Available on www.dundeeprecious.com under Investor Centre
About Dundee Precious Metals Inc.
Dundee Precious...
Form 8.3 – [ADVANCED MEDICAL SOLUTIONS GROUP PLC – 04 04 2025] – (CGWL)
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
ADVANCED MEDICAL SOLUTIONS GROUP PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
N/A(e) Date...
Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Advanced Medical Solutions Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position...
Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Advanced Medical Solutions Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position...
Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Advanced Medical Solutions Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position...
Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Advanced Medical Solutions Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position...
Correction: Form 8.3 – Octopus Investments – Advanced Medical Solutions Group plc
Written by Customer Service on . Posted in Mergers And Acquisitions.
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”)
1. KEY INFORMATION(a) Full name of discloser:
OCTOPUS INVESTMENTS LTD(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree
Advanced Medical Solutions Group plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position...